Abstract 16691: High-Dose versus Standard-Dose Influenza Vaccine in Older Adults with Neurological and Cerebrovascular Disease: A Prespecified Analysis of the DANFLU-2 Trial
Abstract
Background: Adults with neurological or cerebrovascular (NeCVD) disease have an elevated risk of influenza-related complications. Whether HD-IIV provides greater relative benefit over SD-IIV in this population is uncertain. Objective: To evaluate the relative vaccine effectiveness (rVE) of high-dose inactivated influenza vaccine (HD-IIV) compared with standard-dose inactivated influenza vaccine (SD-IIV) among older adults with and without NeCVD disease. Methods: We conducted a prespecified secondary analysis of DANFLU-2, a pragmatic, registry-based, open-label, active-controlled, individually randomized trial in Denmark across the 2022/23, 2023/24, and 2024/25 influenza seasons. Adults aged ≥65 years were randomized 1:1 to HD-IIV or SD-IIV. Outcome data were obtained from nationwide health registries. The primary outcome was hospitalization for influenza or pneumonia. rVE was calculated as rVE = (1 – RR) х 100%. The number needed to vaccinate (NNV) was calculated as 1/(SD-IIV event rate х rVE). NNV was calculated only for endpoints with lower limit of confidence interval of overall crude rVE estimates > 0. NNV within subgroups was calculated using the overall rVE estimate for the outcome in case no significant effect modification was observed. Results: Among 332,438 participants, 166,218 were randomized to HD-IIV and 166,220 to SD-IIV. NeCVD was present in 24,467 (7.4%) of participants. Event rates were higher among participants with NeCVD than those without, including hospitalization for influenza or pneumonia (25.0 vs 10.6 per 1,000 participant-years), cardiorespiratory hospitalization (73.9 vs 35.7), and stroke hospitalization (13.1 vs 4.0). rVE was consistent among participants with and without NeCVD for most outcomes (Pinteraction>0.05). As a result, NNVs were lower among participants with neurological or cerebrovascular disease. For example, for the primary outcome of hospitalization for influenza and pneumonia, rVE was 12.4% (95% CI, -8.1 to 29.0; NNV=502) among those with NeCVD vs 4.9% (95% CI, -3.9 to 13.1; NNV=3,070) among those without. The rVEs for NeCVD outcomes were generally neutral, including all-cause neurological hospitalizations [rVE -14.6% (95% CI, -47.2 to 10.6)] and cerebrovascular hospitalizations [rVE 6.9% (95% CI, -4.4 to 17.0)]. The risk of hemorrhagic stroke was lower with HD-IIVvs SD-IIV [rVE 28.4% (95% CI, 2.4 to 47.7)]. No significant differences were observed for dementia outcomes [rVE 21.7% (95% CI, -51.6 to 60.2)] (Figure 1). Conclusions: The rVE of HD-IIV vs. SD-IIV was consistent across participants with and without knowing NeCVD. Estimated NNVs for HD-IIV vs. SD-IIV were lower among those with NeCVD due to higher underlying event rates. These findings support HD-IIV for high-risk neurovascular populations, where similar rVE may yield greater absolute benefit.